The Ontario government announced that beginning March 31, 2023, Ontario Drug Benefit (ODB) recipients who are on an originator biologic will be required to transition to a Health Canada- approved biosimilar. To help pharmacy professionals expand their knowledge and better their patient care the Alberta Pharmacists’ Association (RxA) is offering CCCEP accredited courses to Ontario pharmacists at a greatly reduced rate.
All three courses are $25 each and offer information about adalimumab that is applicable to pharmacists across Canada.
In this course, pharmacist Aaron Sihota provides an overview of adalimumab pharmacology. Aaron defines biologics and biosimilars, discusses the pharmacology of adalimumab, and outlines factors affecting special populations when starting adalimumab biosimilar therapy. This course is CCCEP accredited for 1.0 CEU.
Join pharmacist Aaron Sihota in this course as he discusses the common adverse effects of the reference biologic adalimumab and its biosimilars and describes how to advise patients about the potential for severe adverse effects of these agents. Aaron also outlines how to appropriately report adverse events to Health Canada and other relevant agencies or groups. This course is CCCEP accredited for 1.0 CEU.
In this course, pharmacist Aaron Sihota identifies the necessary laboratory tests for a patient starting on adalimumab or biosimilar therapy. He outlines communication strategies relevant to patient conversations regarding switching to a biosimilar and discusses strategies to manage the nocebo effect. This course is CCCEP accredited for 0.75 CEUs.